title: Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody.
abstract: OBJECTIVE
  The purpose of this study was to compare the immunohistochemical staining profiles of PAX8-polyclonal, PAX8-monoclonal, PAX5-monoclonal and PAX6-monoclonal antibodies in several histological types of primary thoracic and thyroid tumours. In addition, we analysed PAX8 mRNA expression by using in-situ hybridization.
  
  
  RESULTS
  We compared polyclonal PAX8 and monoclonal PAX8, PAX5 and PAX6 antibodies in 962 samples (687 lung carcinomas, 40 malignant pleural mesotheliomas, 138 thymic tumours and 97 thyroid tumours) using the tissue microarray technique. Among thyroid tumours, the monoclonal and polyclonal PAX8 antibodies showed a high positive rate (98.0%). Of 167 polyclonal PAX8 antibody-positive tumours, except for thyroid tumours, 54 cases tested positive for PAX5 and/or PAX6 (31 lung carcinomas and 23 thymic tumours). No PAX8 mRNA expression was detected using RNAscope (in-situ hybridization technique) other than in thyroid tumours. A portion of polyclonal PAX8 antibody-positive tumours showed cross-reactivity for PAX5 or PAX6 protein.
  
  
  CONCLUSIONS
  Monoclonal PAX8 antibody showed high specificity to thyroid tumours and was superior to the polyclonal antibody.
authors.affiliation: Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan; Department of Pathology, Juntendo University Urayasu Hospital, Chiba, Japan.
authors.forename: Akane
authors.initials: A
authors.lastname: Toriyama
authors.forename: Taisuke
authors.initials: T
authors.lastname: Mori
authors.forename: Shigeki
authors.initials: S
authors.lastname: Sekine
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yoshida
authors.forename: Okio
authors.initials: O
authors.lastname: Hino
authors.forename: Koji
authors.initials: K
authors.lastname: Tsuta
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D015415:Biomarkers / Q000032:analysis; D005136:Eye Proteins / Q000032:analysis / Q000276:immunology; D018398:Homeodomain Proteins / Q000032:analysis / Q000276:immunology; D006801:Humans; D017403:In Situ Hybridization; D008175:Lung Neoplasms / Q000175:diagnosis; D051379:Mice; D051757:PAX5 Transcription Factor / Q000032:analysis / Q000276:immunology; D000071841:PAX6 Transcription Factor; D000072636:PAX8 Transcription Factor; D051761:Paired Box Transcription Factors / Q000032:analysis* / Q000276:immunology*; D010997:Pleural Neoplasms / Q000175:diagnosis; D012097:Repressor Proteins / Q000032:analysis / Q000276:immunology; D013899:Thoracic Neoplasms / Q000175:diagnosis*; D013953:Thymus Neoplasms / Q000175:diagnosis; D013964:Thyroid Neoplasms / Q000175:diagnosis*; D046888:Tissue Array Analysis
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; D005136:Eye Proteins; D018398:Homeodomain Proteins; D051757:PAX5 Transcription Factor; D000071841:PAX6 Transcription Factor; C000605730:PAX6 protein, human; D000072636:PAX8 Transcription Factor; D051761:Paired Box Transcription Factors; C497282:Pax5 protein, mouse; C000605732:Pax6 protein, mouse; C499496:Pax8 protein, mouse; D012097:Repressor Proteins
keywords: PAX8; cross-reactivity; immunohistochemistry; thoracic tumours